2 Blue Chips Under Pressure
Motley Fool Money
00:00
Intro
This chapter analyzes Johnson & Johnson's financial performance in its fiscal year, noting a significant drop in fourth quarter profits due to decreased COVID-19 vaccine demand and inflation. Looking ahead, positive growth is anticipated from its pharmaceutical and medtech segments, alongside the impending separation of its consumer health sector into Kenvue.
Play episode from 00:00
Transcript
